Group 1 - Collegium Pharmaceutical Inc. has entered into an agreement with Corium Therapeutics Holdings for the acquisition of AZSTARYS, involving $650 million in cash payments and potential earn-out considerations of up to $135 million [1][2] - The acquisition is expected to diversify the company's revenue streams beyond pain medicines and strengthen its position in the ADHD market, contributing to revenue through the late 2030s [2] - Collegium's existing operational and marketing capabilities in ADHD are anticipated to enhance margins and increase operating leverage following the acquisition [2] Group 2 - Collegium Pharmaceutical Inc. has been named an official partner of Boston Legacy FC, establishing a multi-year partnership aimed at improving fan experience during home games [3] - The partnership includes the creation of the Collegium Sensory Room at Gillette, Centreville, and White Stadium, designed to provide a peaceful environment for fans during matches [4] - This initiative aims to enhance the overall experience for visitors by offering a safer and more comfortable setting away from the intense match environment [4] Group 3 - Collegium Pharmaceutical Inc. specializes in the development and commercialization of pain management medicines, offering a diverse product range including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR, and Symproic [5]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - Collegium Pharmaceutical is expanding its position in the ADHD market through the acquisition of AZSTARYS and related subsidiaries from Corium Therapeutics [2] Group 1: Acquisition Details - The acquisition of AZSTARYS significantly enhances Collegium's portfolio in the ADHD sector [2] - The call includes participation from key executives, including the President and CEO, Chief Commercial Officer, and Chief Financial Officer, indicating a strong leadership presence for the discussion [2] Group 2: Investor Communication - The company emphasizes that the information presented is not promotional and includes forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act of 1995 [3] - There is a caution regarding the potential differences between future results and current expectations, highlighting the inherent risks and uncertainties [4]

Summary of Collegium Pharmaceutical Investor Call Company Overview - **Company**: Collegium Pharmaceutical (NasdaqGS:COLL) - **Event**: Investor Call regarding the acquisition of AZSTARYS from Corium Therapeutics - **Date**: March 19, 2026 Key Points Acquisition Details - Collegium announced the acquisition of AZSTARYS and relevant subsidiaries from Corium Therapeutics for **$650 million** in cash, with potential contingent payments of up to **$135 million** based on sales and regulatory milestones [8][10][19] - The acquisition is expected to close in the **second quarter of 2026** [19] Strategic Rationale - The acquisition significantly expands Collegium's position in the **ADHD** market, adding a second differentiated treatment alongside **Jornay PM** [5][19] - AZSTARYS is expected to extend ADHD revenues into **2037**, five years beyond Jornay PM's expected loss of exclusivity [7][19] - The deal is aligned with Collegium's capital allocation strategy, balancing portfolio expansion and fiscal responsibility [8][19] Financial Impact - The acquisition is projected to be immediately accretive to adjusted EBITDA, with AZSTARYS expected to generate over **$50 million** in pro forma net revenues in the second half of **2026** [10][11] - Collegium generated over **$329 million** in cash from operations in **2025**, indicating strong cash flow to support the acquisition [9] Market Context - The ADHD market is large and growing, with approximately **22 million** patients in the U.S. and **111 million** prescriptions written in **2025** [12] - ADHD prescriptions have been growing at about **8% annually** over the past five years, with **90%** of prescriptions for stimulant medications [12] Product Differentiation - Jornay PM is unique as it is taken at night and provides efficacy upon awakening, while AZSTARYS combines fast and long-acting medications in one capsule [15][17] - Both products target different patient needs, with Jornay PM primarily used in children and adolescents, and AZSTARYS having a more balanced distribution between adults and children [17][18] Sales and Marketing Strategy - Collegium plans to leverage its existing ADHD commercial infrastructure to drive growth for both products, expecting significant cost synergies of over **$50 million** within 12 months post-acquisition [10][19] - The company has a sales force of **180 representatives**, compared to Corium's **100**, which will enhance marketing efforts for AZSTARYS [30][37] Future Outlook - Collegium remains open to further acquisitions in both ADHD and potentially other therapeutic areas, maintaining a focus on capital-efficient opportunities [50][51] - The company aims to maximize the potential of both Jornay PM and AZSTARYS, ensuring broad access and support for the ADHD community [45][54] Additional Insights - Healthcare professionals have rated both Jornay PM and AZSTARYS highly, with **70%** indicating a strong intent to increase prescribing of Jornay PM and **53%** for AZSTARYS [15][16] - The acquisition reflects Collegium's commitment to innovation and financial discipline, aiming to create long-term shareholder value [19][21] Conclusion - The acquisition of AZSTARYS is a strategic move for Collegium, enhancing its ADHD portfolio and positioning the company for sustained growth and shareholder value creation in the biopharmaceutical sector [21][64]

Summary of Collegium Pharmaceutical Investor Call Company Overview - **Company**: Collegium Pharmaceutical (NasdaqGS: COLL) - **Industry**: Biopharmaceuticals, specifically focusing on ADHD and pain management Key Points from the Call Acquisition Announcement - Collegium announced the acquisition of **AZSTARYS** and relevant corporate subsidiaries from **Corium Therapeutics** for **$650 million** in cash, with potential contingent payments of up to **$135 million** based on sales and regulatory milestones [2][8][19] - This acquisition significantly expands Collegium's position in the ADHD market, complementing its existing product **Jornay PM** [2][5] Strategic Rationale - The acquisition is seen as a strategic addition that accelerates growth and enhances patient care, with a focus on differentiated commercial medicines that have exclusivity into the **2030s** and beyond [4][5] - AZSTARYS is expected to extend future ADHD revenues into **2037**, five years beyond Jornay PM's expected loss of exclusivity [7][19] Financial Implications - The acquisition is expected to be immediately accretive to adjusted EBITDA, with AZSTARYS projected to generate over **$50 million** in pro forma net revenues in the second half of **2026** [10][11] - Collegium generated over **$329 million** in cash from operations in **2025**, indicating strong cash flow to support the acquisition [9] Market Dynamics - The ADHD market is large and growing, with approximately **22 million** patients in the U.S. and **111 million** prescriptions written in **2025** [12] - Prescriptions for ADHD have been growing at about **8%** annually over the past five years, with **90%** of prescriptions for stimulant medications [12] Product Differentiation - **Jornay PM** is unique as it is taken at night and provides efficacy upon awakening, while **AZSTARYS** combines fast and long-acting medications in one capsule, addressing different patient needs [15][17] - Both products are expected to be complementary, with **70%** of healthcare professionals indicating a strong intent to increase prescribing of Jornay PM and **53%** for AZSTARYS [15][16] Operational Synergies - Collegium plans to leverage its existing ADHD commercial infrastructure to achieve significant cost synergies, estimated to exceed **$50 million** within 12 months post-acquisition [10] - The combined sales force will enhance market access and operational efficiencies, allowing for better service to the ADHD community [18] Future Outlook - Collegium remains focused on executing its strategy of driving growth through business development, with an openness to exploring other therapeutic areas, including rare diseases [49][50] - The company plans to update its financial guidance for **2026** following the transaction's closure, expected in the second quarter [11][19] Additional Insights - The acquisition aligns with Collegium's capital allocation strategy, balancing portfolio expansion with fiscal responsibility [8] - The company emphasizes its commitment to improving patient care and delivering shareholder value through strategic acquisitions and operational efficiencies [21][22]

Core Viewpoint - Collegium Pharmaceutical plans to acquire the ADHD drug AZSTARYS and related subsidiaries from Corium Therapeutics for $650 million, aiming to enhance its ADHD product portfolio and revenue stability [1][2]. Transaction Terms and Timing - The acquisition will be funded through cash on hand and a $300 million delayed-draw term loan, with an expected interest rate of SOFR plus 325 basis points [2]. - The deal is anticipated to close in the second quarter of 2026, with updated financial guidance to be provided post-transaction [3]. Strategic Rationale - The acquisition is part of a strategic initiative to diversify beyond pain management and strengthen Collegium's position in the ADHD market, leveraging existing commercial infrastructure [4]. - By adding AZSTARYS, the company aims to extend its ADHD revenue stream into 2037, five years beyond the expected loss of exclusivity for Jornay PM [5]. Financial Expectations and Synergy Targets - The transaction is expected to be immediately accretive to adjusted EBITDA, with increased financial benefits anticipated starting in 2027 [6]. - Collegium reported over $329 million in cash from operations in 2025 and expects strong cash generation in the following years, with a projected net debt to adjusted EBITDA ratio of approximately 2x post-acquisition [6][7].

Collegium to Acquire AZSTARYS® from Corium Therapeutics March 19, 2026 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that c ...

Core Viewpoint - Collegium Pharmaceutical, Inc. is acquiring AZSTARYS from Corium Therapeutics for $650 million in cash, with potential additional milestone payments of up to $135 million, which is expected to enhance Collegium's ADHD portfolio and financial position significantly [2][3][4]. Transaction Overview - The acquisition is expected to generate over $50 million in pro forma net revenue in the second half of 2026 and is anticipated to be immediately accretive to adjusted EBITDA [1][7][13]. - The transaction will be funded through Collegium's cash on hand and a previously announced $300 million delayed draw term loan [1][13]. - The deal has been unanimously approved by the boards of directors of both companies and is expected to close in the second quarter of 2026, pending regulatory approvals [8]. Strategic Rationale - The acquisition aligns with Collegium's mission to build a diversified biopharmaceutical company and strengthens its position in the ADHD market [7]. - AZSTARYS is the first and only ADHD treatment combining immediate release and long-acting medications in one capsule, which complements Collegium's existing ADHD products [3][4]. - The acquisition is expected to leverage Collegium's established ADHD commercial infrastructure, driving operational efficiencies and increasing revenue scale [7]. Financial Impact - AZSTARYS generated over 760,000 prescriptions in 2025, indicating strong market demand and potential for revenue growth [7]. - Collegium expects annual run rate synergies exceeding $50 million within twelve months post-closing, further enhancing its financial position [7]. - The acquisition is supported by six Orange Book-listed patents, extending the longevity of Collegium's ADHD portfolio into 2037 and beyond [7].

Core Insights - Zevra Therapeutics has reached an agreement with Commave Therapeutics to sell its serdexmethylphenidate (SDX) portfolio for $50 million, which includes products AZSTARYS and KP1077 [1][2] - The sale resolves a previous litigation initiated by Commave against Zevra in 2024, stemming from a 2019 licensing agreement [2] - Following the agreement, Zevra has fully repaid its $63 million term loan, resulting in a debt-free balance sheet and improved financial flexibility [3] Company Overview - Zevra Therapeutics is a commercial-stage company focused on developing therapies for rare diseases, with a commitment to expanding access and progressing its pipeline [4] - The company’s lead product targets Niemann-Pick disease type C (NPC), a rare neurodegenerative condition, which validates its capability to bring therapies from development to market [4] - Zevra's strategic plan emphasizes patient centricity, integrity, accountability, innovation, and courage to deliver long-term value [4]

Summary of Zevra Therapeutics FY Conference Call Company Overview - **Company**: Zevra Therapeutics (NasdaqGS: ZVRA) - **Industry**: Rare Disease Therapeutics - **Lead Product**: MIPLYFFA for Niemann-Pick disease type C (NPC) - **Financial Position**: Net revenue of $72.3 million in the first nine months of 2025, with a cash position of $230.4 million at the end of Q3 2025 [2][5][30] Core Points and Arguments Company Mission and Vision - Zevra aims to redefine possibilities in rare disease therapies, focusing on patient-centricity and accountability to stakeholders [4][5] - The company is in growth mode with a late-stage pipeline and geographic expansion plans [5][10] Product and Market Performance - MIPLYFFA received FDA approval in September 2024 and has orphan drug exclusivity until 2031 [5][6] - The product has achieved approximately 40% penetration of the diagnosed patient population within the first 12 months post-launch, a notable achievement in the rare disease space [10][19] - The company is expanding access to MIPLYFFA in Europe, with an MAA under review by the EMA [5][11] Pipeline and Future Growth - Zevra has a diversified portfolio including OLPRUVA for urea cycle disorders and AZSTARYS, with various products under development [6][28] - Celiprolol is in a pivotal phase 3 trial for vascular Ehlers-Danlos syndrome (VEDS) [28] - The company is leveraging AI for patient identification and diagnosis, enhancing its market reach [22][39] Financial Discipline and Strategy - Strong balance sheet with $230.4 million in cash and $61 million in debt [30] - The company monetized a pediatric priority review voucher for $150 million, adding non-dilutive capital [13] - Focus on sustainable growth through disciplined investments and prioritization of high-value opportunities [9][30] Important but Overlooked Content - The company is actively working on expanding its geographic reach beyond the U.S. and Europe, with distribution agreements in place for markets outside these regions [25][50] - The potential for patent term extension could significantly impact the company's valuation, with a ruling expected in 2026 [52][53] - The total addressable market (TAM) for NPC is estimated between 300 to 900 patients in the U.S., with ongoing efforts to identify undiagnosed patients [21][23] Conclusion Zevra Therapeutics is positioned for significant growth in the rare disease therapeutics market, driven by its innovative product MIPLYFFA, a strong financial foundation, and strategic expansion efforts. The company is focused on enhancing patient access and leveraging its pipeline to solidify its market presence.